Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 23;11(6):e220021.
doi: 10.1530/EC-22-0021. Print 2022 Jun 1.

Impact of parathyroidectomy on quality of life in multiple endocrine neoplasia type 1

Affiliations

Impact of parathyroidectomy on quality of life in multiple endocrine neoplasia type 1

Marília D'Elboux Guimarães Brescia et al. Endocr Connect. .

Abstract

Background: Potential influences of parathyroidectomy (PTx) on the quality of life (QoL) in multiple endocrine neoplasia type 1-related primary hyperparathyroidism (HPT/MEN1) are unknown.

Method: Short Form 36 Health Survey Questionnaire was prospectively applied to 30 HPT/MEN1 patients submitted to PTx (20, subtotal; 10, total with autograft) before, 6 and 12 months after surgery. Parameters that were analyzed included QoL, age, HPT-related symptoms, general pain, comorbidities, biochemical/hormonal response, PTx type and parathyroid volume.

Results: Asymptomatic patients were younger (30 vs 38 years; P = 0.04) and presented higher QoL scores than symptomatic ones: Physical Component Summary score (PCS) 92.5 vs 61.2, P = 0.0051; Mental Component Summary score (MCS) 82.0 vs 56.0, P = 0.04. In both groups, QoL remained stable 1 year after PTx, independently of the number of comorbidities. Preoperative general pain was negatively correlated with PCS (r = -0.60, P = 0.0004) and MCS (r = -0.57, P = 0.0009). Also, moderate/intense pain was progressively (6/12 months) more frequent in cases developing hypoparathyroidism. The PTx type and hypoparathyroidism did not affect the QoL at 12 months although remnant parathyroid tissue volume did have a positive correlation (P = 0.0490; r = 0.3625) to PCS 12 months after surgery. Patients with one to two comorbidities had as pre-PTx PCS (P = 0.0015) as 12 months and post-PTx PCS (P = 0.0031) and MCS (P = 0.0365) better than patients with three to four comorbidities.

Conclusion: A variable QoL profile was underscored in HPT/MEN1 reflecting multiple factors associated with this complex disorder as comorbidities, advanced age at PTx and presence of preoperative symptoms or of general pain perception. Our data encourage the early indication of PTx in HPT/MEN1 by providing known metabolic benefits to target organs and avoiding potential negative impact on QoL.

Keywords: hyperparathyroidism; hypoparathyroidism; multiple endocrine neoplasia type 1; parathyroidectomy; quality of life.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of included patients. *(n  = 1) neck re-operation by persistence of HPT. AG, autograft; HPT/MEN1, multiple endocrine neoplasia type 1-related primary hyperparathyroidism; SPTx, subtotal parathyroidectomy; SF-36, Short Form 36 Health Survey Questionnaire; TPTx+AG, total parathyroidectomy with autograft.
Figure 2
Figure 2
PCS and MCS before and after the operation according to preoperative symptoms. mo, months; PCS, Physical Component Summary score, pre, preoperative; MCS, Mental Component Summary score.
Figure 3
Figure 3
Postoperative changes in the median quality of life scores (PCS and MCS) according to definitive HYPO after the operation. HYPO, hypoparathyroidism; PCS, Physical Component Summary score, pre, preoperative; mo, months; MCS, Mental Component Summary score.

References

    1. Thakker RV, Newey PJ, Walls GV, Bilezikian J, Dralle H, Ebeling PR, Melmed S, Sakurai A, Tonelli F, Brandi MLet al.Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). Journal of Clinical Endocrinology and Metabolism 2012972990–3011. (10.1210/jc.2012-1230) - DOI - PubMed
    1. Brandi ML, Agarwal SK, Perrier ND, Lines KE, Valk GD, Thakker RV. Multiple endocrine neoplasia type 1: latest insights. Endocrine Reviews 202142133–170. (10.1210/endrev/bnaa031) - DOI - PMC - PubMed
    1. Lourenço Jr DM, Toledo RA, Mackowiak II, Coutinho FL, Cavalcanti MG, Correia-Deur JE, Montenegro F, Siqueira SA, Margarido LC, Machado MCet al.Multiple endocrine neoplasia type 1 in Brazil: MEN1 founding mutation, clinical features, and bone mineral density profile. European Journal of Endocrinology 2008159259–274. (10.1530/EJE-08-0153) - DOI - PubMed
    1. Toledo SP, Lourenço Jr DM, Toledo RA. A differential diagnosis of inherited endocrine tumors and their tumor counterparts. Clinics 2013681039–1056. (10.6061/clinics/2013(0724) - DOI - PMC - PubMed
    1. Kamilaris CDC, Stratakis CA. Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Frontiers in Endocrinology 201910 339. (10.3389/fendo.2019.00339) - DOI - PMC - PubMed

LinkOut - more resources